Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)
Others
Ratios

BioLineRx (BLRX) Revenue (2023 - 2025)

Historic Revenue for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $427000.0.

  • BioLineRx's Revenue fell 9136.15% to $427000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year decrease of 2167.41%. This contributed to the annual value of $28.9 million for FY2024, which is 50291.67% up from last year.
  • Per BioLineRx's latest filing, its Revenue stood at $427000.0 for Q3 2025, which was down 9136.15% from $304000.0 recorded in Q2 2025.
  • BioLineRx's 5-year Revenue high stood at $11.7 million for Q4 2024, and its period low was -$932000.0 during Q4 2023.
  • Its 3-year average for Revenue is $3.1 million, with a median of $882000.0 in 2023.
  • Its Revenue has fluctuated over the past 5 years, first skyrocketed by 136062.23% in 2024, then crashed by 9628.01% in 2025.
  • Quarter analysis of 3 years shows BioLineRx's Revenue stood at -$932000.0 in 2023, then skyrocketed by 1360.62% to $11.7 million in 2024, then plummeted by 96.37% to $427000.0 in 2025.
  • Its Revenue was $427000.0 in Q3 2025, compared to $304000.0 in Q2 2025 and $255000.0 in Q1 2025.